/assets/images/provider/photos/2850470.jpg)
In short…
SPRAVATO® has gained a reputation for being a highly effective treatment-resistant depression treatment. According to a study published by the National Institutes of Health, two separate trials demonstrated that those with major depressive disorder who were administered SPRAVATO® experienced significant improvement within 24 hours of their first dose.
This article will explore what SPRAVATO® really is, how it works, and how it benefits patients who are looking for relief.
Treatment-resistant depression (TRD) is depression that hasn’t improved after trying at least two different antidepressant medications at adequate doses and durations.
TRD significantly impacts daily functioning and, according to the National Institutes of Health, it impacts at least 30 percent of individuals diagnosed with major depressive disorder.
Individuals with TRD often experience life-altering symptoms, including:
TRD can also increase the risk of suicidal thoughts and behaviors, highlighting the need for effective interventions.
The exact causes of TRD are not fully understood, but research suggests a complex interplay of biological, psychological, and environmental factors.
It is widely thought that genetic predisposition may play a role in the development of TRD. Other contributing factors include neurotransmitter imbalances, such as:
Life experiences, living environments, and other social and psychological factors can be risk factors. These include:
It’s important to note that some medications and medical conditions may include side effects or mimic symptoms of depression.
Healthcare professionals typically look out for:
SPRAVATO® (esketamine) represents a significant advancement in the treatment of treatment-resistant depression (TRD). Unlike traditional antidepressants, SPRAVATO® works through a different mechanism of action, offering hope for individuals who haven’t found relief with conventional treatments.
SPRAVATO® (esketamine) is a nasal spray medication approved by the FDA for the treatment of treatment-resistant depression in adults.
It works differently from traditional antidepressants by targeting the NMDA receptor in the brain. Because of its innovative mechanics, SPRAVATO® must be administered under the supervision of a healthcare provider in a certified treatment center.
SPRAVATO® is believed to increase levels of glutamate, a neurotransmitter that plays a role in mood regulation. By modulating glutamate activity, it can help restore connections between brain cells and improve mood.
It is important to note that SPRAVATO® is typically used in conjunction with an oral antidepressant.
SPRAVATO® differs significantly from traditional antidepressants in its mechanism, administration, and speed of action. While both aim to alleviate symptoms of treatment-resistant depression, SPRAVATO® offers a unique approach for individuals who may not respond well to standard antidepressant treatments.
Embarking on SPRAVATO® treatment involves an initial assessment, administration, and ongoing monitoring. Open communication with your healthcare provider is essential throughout the process.
A thorough psychiatric evaluation is necessary to determine if SPRAVATO® is appropriate for you. This evaluation may include a review of:
Your provider will discuss the potential benefits and risks of SPRAVATO® with you.
SPRAVATO® is administered as a nasal spray in a certified treatment center. During treatment, you will self-administer the nasal spray under the supervision of your healthcare professional.
After each dose, you will be monitored for at least two hours for potential side effects.
Common side effects of SPRAVATO® include:
Your blood pressure may also be monitored before and after each dose.
You will be advised not to drive or operate heavy machinery until the day after each treatment session, so it is important to arrange for someone to drive you home from your appointment.
To maximize the benefits of treatment-resistant depression treatment, including SPRAVATO®, it’s essential to adopt a holistic approach that combines medication with other therapies and lifestyle modifications.
Combining SPRAVATO® with other treatments can help enhance its efficacy. Consider:
Making simple lifestyle adjustments can support your mental health journey. It is often recommended that patients with TRD try to:
There are many ways in which patients can manage their treatment-resistant depression. Key strategies to implement include:
Recognizing when to seek professional help for TRD is crucial. If you are in immediate danger or experiencing active suicidal thoughts, call or text 988 (Suicide & Crisis Lifeline) or go to the nearest emergency room immediately.
At My Buoyant Health in Phoenix, Arizona, we offer comprehensive TRD treatment, including SPRAVATO®.
Watch out for warning signs of TRD, including:
Seek out a psychiatrist or other mental health professional who specializes in the treatment of TRD.
If you are interested in SPRAVATO® for treatment-resistant depression treatment, ensure that your preferred provider is experienced in administering SPRAVATO® and managing potential side effects.
At My Buoyant Health, we specialize in offering effective treatment for treatment-resistant depression through SPRAVATO® (esketamine). Our skilled providers are extensively trained to administer this innovative therapy in a safe, comfortable, and supportive environment. We are dedicated to creating a welcoming space where patients can find relief, regain hope, and take meaningful steps toward reclaiming their well-being.
To learn more about SPRAVATO® or to get started on your journey to a more balanced life, call My Buoyant Health today at (602) 510-6582 or use our online appointment request form.